First Ozempic Generics Approved in Canada, Seen as Test Case for Novo Nordisk
Health Canada has approved the first generic versions of Novo Nordisk's Ozempic, developed by Dr. Reddy's Laboratories and Apotex. While these generics are only available in Canada, analysts suggest they could signal the beginning of a decline in international revenue for semaglutide, the active ingredient in Ozempic and Wegovy. Novo Nordisk expects a low single-digit impact from generics.
Topics: Canada generics GLP-1 Novo Nordisk Ozempic semaglutide